Bioequivalence of Two Liraglutide Formulations in Healthy Volunteers

NCT01515553 · Completed

Last updated 2026-05-28

This clinical trial tested whether two different versions of the diabetes medication liraglutide are absorbed equally in the bodies of healthy volunteers.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 22 people

Who can join Ages 18–50 · all sexes

Timeline Started 2007-01 · est. completion 2007-04

Where 1 site · Sweden

What this study is testing ClinicalTrials.gov NCT01515553 ↗

Description as written by the study sponsor.

This trial is conducted in Europe. The aim of this trial is to test for bioequivalence of the phase 3a formulation of liraglutide (formulation 4) and the liraglutide formulation planned for phase 3b trials (final formulation 4).

Treatments tested

liraglutide Drug

Two single doses of 0.72 mg liraglutide administered subcutaneously on two different dosing occasions separated by a wash-out period

Main thing measured	Area under the curve (0-t)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Healthy
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01515553 ↗